Drug Discovery@nature.com 15 November 2013

Advertisement Tired of teaching new software to your staff and colleagues? Real-time PCR can be so easy and intuitive. Click here to watch a 5 minute video featuring the LightCycler® 96 Software 1.1. TABLE OF CONTENTS 15 November 2013 News Analysis Research Highlights Research & Reviews Careers Advertisement   Reichert Life Sciences Surface Plasmon Resonance (SPR) Systems - Drug discovery instruments for real-time, label-free results Reichert SPR systems generate precise kinetics (on/off rates), affinity and thermodynamics data for lead optimization. The ultra-sensitive systems are flexible and affordable. Read citations of Reichert systems in peer-reviewed abstracts.  ReichertSPR.com Nature Reviews Drug Discovery is on Twitter Advertisement Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer  Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.    News Top United States to approve potent oral drugs for hepatitis C doi:10.1038/nature.2013.14059 Improved treatments offer hope for eradication of viral liver infection. Full Text Dual-action drug shows promise against diabetes doi:10.1038/nature.2013.14062 Molecule controls blood sugar effectively in humans and also promotes weight loss in rodents. Full Text A promise to a court doesn't avoid infringement doi:10.1038/nrd4170 Generics manufacturer Dr Reddy’s has been unsuccessful in trying to show that its generic version of the insomnia drug Lunesta (eszopiclone) would not infringe on a patent that protects Lunesta. Full Text An audience with...Dan Tagle doi:10.1038/nrd4153 The NIH's Dan Tagle discusses the promise of extracellular RNA, the focus of a US$17 million funding programme. Full Text Analysis Top ALS antisense oligonucleotides doi:10.1038/scibx.2013.1210 Isis and three academic groups are developing antisense oligonucleotide therapeutics for the most common cause of ALS. The drugs target hexanucleotide repeat expansions in C9orf72 and mitigate neurotoxicity in vitro. Full Text Advances in prostate cancer treatment doi:10.1038/nrd4068 This article examines current and upcoming treatment modalities and provides a market outlook for prostate cancer. Full Text Research Highlights Top Anticancer drugs: IDH2 drives cancer in vivo doi:10.1038/nrd4160 Two recent studies show that mutations in the metabolic gene isocitrate dehydrogenase 2 (IDH2) can drive the development of leukaemia and sarcoma in vivo. Full Text Neurodegenerative disorders: A PIR-fect storm doi:10.1038/nrd4159 This study shows that ‘immune receptors’ may have a role in Alzheimer’s disease and points to leukocyte immunoglobulin-like receptor B2 (LILRB2) as a potential therapeutic target for this disorder. Full Text Lysosomal storage diseases: Thioesterase mimetic reduces toxicity doi:10.1038/nrd4156 This study reports a small hydroxylamine derivative that delayed neurological deterioration and extended lifespan in a mouse model of infantile neuronal ceroid lipofuscinosis (INCL) - a neurodegenerative lysosomal storage disease. Full Text Research & Reviews Top Metabolic targets for cancer therapy doi:10.1038/nrd4145 Here, the authors discuss the intimate relationship between metabolism and malignancy, focusing on therapeutic strategies and emerging agents targeting the metabolic rearrangements of cancer cells. Full Text Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain doi:10.1038/nrd3893 Glycine transporters are important regulators of the level of glycine, which can act as both an inhibitory neurotransmitter and a modulator of neuronal excitation. Here, the authors discuss the potential of glycine transporters as novel therapeutic targets for schizophrenia, alcohol dependence and pain. Full Text Immunological functions of the neuropilins and plexins as receptors for semaphorins doi:10.1038/nri3545 Semaphorins and their primary receptors, the neuropilins and plexins, participate in a wide range of innate and adaptive immune responses, which has implications for immune disorders such as multiple sclerosis, rheumatoid arthritis and allergy. Full Text Microbiota-mediated colonization resistance against intestinal pathogens doi:10.1038/nri3535 Colonization resistance - protection from exogenous pathogens by commensal bacteria - can be mediated by direct antagonism and by indirect effects on the host immune response. This Review outlines our current knowledge of immune-mediated colonization resistance against clinically relevant, antibiotic-resistant intestinal pathogens and how insights into commensal bacterial species and their mechanisms might be therapeutically used to restore resistance. Full Text Drug Discovery JOBS of the week Imaging of control drug release materials using hyperpolarised 129Xe MRI The University of Nottingham Postdoctoral Researcher in Biomaterials and Drug Delivery Vanderbilt University, Department of Chemical and Biomolecular Engineering Chemistry Faculty Position, Drug Discovery Department, Moffitt Cancer Center Moffitt Cancer Center Post-Doctoral Research Fellow, Drug Discovery Fred Hutchinson Cancer Research Center Postdoc Position – Cancer Drug Resistance Brigham & Women's Hospital - Harvard Medical School More Science jobs from Drug Discovery EVENT Oncology imaging for drug development 12.03.14 London, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.